受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | NDI-010976 | Storage (From the date of receipt) |
3 years -20°C powder | |
化学式 | C28H31N3O8S |
|||
分子量 | 569.63 | CAS No. | 1434635-54-7 | |
Solubility (25°C)* | 体外 | DMSO | 100 mg/mL (175.55 mM) | |
Ethanol | 4 mg/mL (7.02 mM) | |||
Water | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | Firsocostat (GS-0976, ND-630) is a reversible inhibitor of acetyl CoA carboxylase (ACC) with IC50s of 2.1 nM,6.1 nM for hACC1 and hACC2,respectively. |
---|---|
in vitro | When ND-630 and [14C]acetate were administered to Hep-G2 cells for 4 h, ND-630 inhibited FASyn with EC50 values of 66 nM in cells cultured in medium containing. When ND-630 and[14C]palmitate were administered to C2C12 cells for 6 h, ND-630 increased both the release of [14C]O2 and the production of[14C]acid-soluble material.[1] |
in vivo | When administered chronically to rats with diet-induced obesity, ND-630 reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia.[1] |
細胞アッセイ | 細胞株 | HepG2 cells |
---|---|---|
濃度 | 2.1 nM (ACC1); 6.1 nM (ACC2) | |
反応時間 | 1 h | |
実験の流れ | Cells were treated with varying concentrations of ND-630. |
|
動物実験 | 動物モデル | Male Sprague–Dawley rats |
投薬量 | 10 mg/kg | |
投与方法 | o.g. |
De novo lipogenesis fuels adipocyte autophagosome and lysosome membrane dynamics [ Nat Commun, 2023, 14(1):1362] | PubMed: 36914626 |
Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease [ Genome Med, 2022, 14(1):67] | PubMed: 35739588 |
Macrophage acetyl-CoA carboxylase regulates acute inflammation through control of glucose and lipid metabolism [ Sci Adv, 2022, 8(47):eabq1984] | PubMed: 36417534 |
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer [ NAT CANCER, 2021, 2, 201–217] | PubMed: None |
Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies [ Cancer Metab, 2021, 9(1):31] | PubMed: 34399819 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。